Quick Answer
Aura Biosciences, Inc. reported R&D Expense of $90.30 million for fiscal year 2025.
Aura Biosciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $90.30M | +23.2% |
| 2024 | $73.30M | +12.4% |
| 2023 | $65.23M | +54.4% |
| 2022 | $42.24M | +67.9% |
| 2021 | $25.16M | +39.5% |
| 2020 | $18.04M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.18M | +30.2% | -3.1% |
| June 30, 2025 | $22.88M | +35.6% | -2.0% |
| March 31, 2025 | $23.34M | +36.9% | +37.0% |
| September 30, 2024 | $17.04M | +10.4% | +0.9% |
| June 30, 2024 | $16.88M | +11.6% | -1.0% |
| March 31, 2024 | $17.05M | +18.4% | +10.5% |
| September 30, 2023 | $15.43M | +36.6% | +2.0% |
| June 30, 2023 | $15.12M | +59.0% | +5.0% |
- Aura Biosciences, Inc. showed an increase of +23.2% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Aura Biosciences, Inc.’s r&d expense has grown by 400.5% (from $18.04 million to $90.30 million).
- The most recent figure is from Aura Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: